Amgen Inc. $AMGN Shares Sold by Tema Etfs LLC

Key Points

• Tema Etfs LLC reduced its holdings in Amgen Inc. by 12.9%, selling 1,445 shares and now owns a total of 9,734 shares worth approximately $3.03 million.
• Amgen reported $6.02 EPS for the last quarter, beating estimates by $0.74, with a revenue of $9.18 billion, reflecting a 9.4% increase year-over-year.
• The company has announced a quarterly dividend of $2.38 per share, yielding about 3.3%, which is significant for shareholder returns.

Tema Etfs LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 12.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,734 shares of the medical research company's stock after selling 1,445 shares during the period. Tema Etfs LLC's holdings in Amgen were worth $3,033,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in AMGN. GAMMA Investing LLC raised its stake in shares of Amgen by 43,573.5% during the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock valued at $1,140,768,000 after purchasing an additional 3,653,205 shares during the period. Nuveen LLC bought a new stake in shares of Amgen in the first quarter worth $688,868,000. Two Sigma Advisers LP increased its stake in shares of Amgen by 96.9% in the fourth quarter. Two Sigma Advisers LP now owns 1,545,600 shares of the medical research company's stock worth $402,845,000 after buying an additional 760,700 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Amgen in the fourth quarter worth $193,339,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Amgen by 15.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,128,328 shares of the medical research company's stock worth $1,336,647,000 after buying an additional 685,785 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on AMGN shares. Morgan Stanley lifted their price target on shares of Amgen from $330.00 to $333.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. UBS Group dropped their price target on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a research note on Wednesday, August 6th. Mizuho lifted their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 7th. Bank of America lifted their price target on shares of Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a research note on Wednesday, July 23rd. Finally, Wall Street Zen lowered shares of Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $304.43.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 1,267 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.76% of the company's stock.

Amgen Stock Performance

AMGN stock traded up $2.10 during trading on Friday, hitting $287.71. 1,302,709 shares of the company's stock traded hands, compared to its average volume of 2,094,510. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $339.17. The stock has a fifty day moving average price of $293.13 and a two-hundred day moving average price of $292.90. The stock has a market capitalization of $154.89 billion, a price-to-earnings ratio of 23.52, a price-to-earnings-growth ratio of 2.50 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the previous year, the company posted $4.97 earnings per share. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 22nd will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 annualized dividend and a dividend yield of 3.3%. Amgen's payout ratio is 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.